Postsurgical Follow-Up and Management

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 125)

Abstract

All patients with medullary thyroid carcinoma (MTC) should undergo calcitonin (CT) determination at regular intervals after total thyroidectomy. Within 6 weeks after operation serum CT measurement has to be performed to determine whether residual tumor or metastases are present (Fig. 1). Patients with normal basal and pentagastrin-stimulated CT levels suggest a tumor-free state where no further treatment is necessary. They can then be followed-up at half-year intervals with physical examinations, and once a year a pentagastrin stimulation test has to be done (Grauer et al. 1990).

Keywords

Adenoma Oncol Diarrhea Doxorubicin Calcitonin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahlman H, Tisell LE (1987) The use of a long acting somatostatin analogue in the treatment of advanced endocrine malignancies with gastrointestinal symptoms. Scand J Gastroenterol 22: 938–942PubMedCrossRefGoogle Scholar
  2. Ahuja S, Ernst H (1987) Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10: 303–310PubMedGoogle Scholar
  3. Athanassiades P, Piperingos G, Pandos P, Koutras D, Moulopoulos S (1988) Serial serum calcitonin concentrations to evaluate responses to therapy of patients with medullary thyroid carcinoma. Chemotherapy 7: 195–197Google Scholar
  4. Bayraktar M, Gedik O, Akalin S, Usman A, Adalara N, Telatar F (1990) The effect of radioactive iodine treatment on thyroid C-cells. Clin Endocrinol (Oxf) 33: 625–630CrossRefGoogle Scholar
  5. Benker G, Reinwein D (1983) Ergebnisse der Chemotherapie des Schilddrüsencarcinoms. Dtsch Med Wochenschr 108: 403–406PubMedCrossRefGoogle Scholar
  6. BenMrad MD, Gardet P, Roche A, Rougier P, Calmettes C, Motte P, Parmentier C (1989) Value of venous catheterization and calcitonin studies in the treatment and management of clinical inapparent medullary thyroid carcinoma. Cancer 63: 133–138PubMedCrossRefGoogle Scholar
  7. Bergholm U, Adami HO, Bergström R, Johannsson H, Lundell G, Telenius-Berg M, Ackerström G (1989) Clinical characteristics in sporadic and familial medullary thyroid carcinoma, a nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer 63: 1196–1204PubMedCrossRefGoogle Scholar
  8. Bergholm U, Adami HO, Bergström R, Bäckdahl M, Ackerström G (1990) Longterm survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. Acta Chir Scand 156: 37–46PubMedGoogle Scholar
  9. Bertagna XY, Bloomgarden ZT, Rabin D, Roberts LJ, Orth DN (1980) Molecular weight forms of immunoreactive calcitonin in a patient with medullary carcinoma of the thyroid: dynamic studies with calcium, pentagastrin, and somatostatin. Clin Endocrinol (Oxf) 13: 115–123CrossRefGoogle Scholar
  10. Body JJ, Mirkine NLD, Corvilain J (1988) Calcitonin deficiency after radioactive iodine treatment. Ann Intern Med 109: 590–591PubMedGoogle Scholar
  11. Buhr HI, Lehnert T, Raue F (1990) New operative strategy in the treatment of metastasizing medullary carcinoma of the thyroid. Eur J Surg Oncol 16: 366–369PubMedGoogle Scholar
  12. Bukowski RM, Brown L, Weik JK, Groppe CW, Purvis J (1983) Combination chemotherapy of metastatic thyroid cancer, phase II study. Am J Clin Oncol 6: 579–581PubMedGoogle Scholar
  13. Chong GC, Beahrs OH, Sizemore GW, Woolner LH (1975) Medullary carcinoma of the thyroid gland. Cancer 35: 695–704PubMedCrossRefGoogle Scholar
  14. Clements D, Webb J, Heath D, McMaster P, Elias E (1986) SMS 201–995 and endocrine tumours. Scand J Gastroenterol 21 Suppl 119: 251–255CrossRefGoogle Scholar
  15. Deftos LJ, Stein MF (1980) Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma. J Clin Endocrinol Metab 50: 967–968PubMedCrossRefGoogle Scholar
  16. Droz JP, Schlumberger M, Rougier P, Caillon B, Godefroy W, Gardet P, Parmentier C (1985) Phase II trials of chemotherapy with adriamycin, cisplatin and their combination in thyroid cancer — a review of 44 cases. In: Jaffiol C, Milhaud G (eds) Thyroid cancer. Elsevier, Amsterdam, pp 203–208Google Scholar
  17. Droz JP, Schlumberger M, Rougier P, Ghosu M, Gardet P, Parmentier C (1990) Chemotherapy in metastatic non anaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76: 480–483PubMedGoogle Scholar
  18. Feinstein RE, Gimeno EJ, el-Salhy M, Wilander E, Walinder G (1986) Evidence of C-cell destruction in the thyroid gland of mice exposed to high 131-I doses. Acta Radiol [Oncol] 25: 199–202CrossRefGoogle Scholar
  19. Fletcher JR (1970) Medullary (solid) carcinoma of the thyroid gland, a review of 249 cases. Arch Surg 100: 257–262PubMedCrossRefGoogle Scholar
  20. Frank K, Raue F, Lorenz D, Herfarth C, Ziegler R (1987) Importance of ultrasound examination for the follow-up of medullary thyroid carcinoma: comparison with other localization methods. Henry Ford Hosp Med J 35: 122–123PubMedGoogle Scholar
  21. Frank-Raue K, Raue F, Buhr HJ, Baldauf G, Lorenz D, Ziegler R (1992) Localization of occult medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid 2: 113–117PubMedCrossRefGoogle Scholar
  22. Gagel RF, Palmer WN, Leonhart K, Chan L, Leong SS (1986) Somatostatin production by a human medullary thyroid carcinoma cell line. Endocrinology 118: 1643–1651PubMedCrossRefGoogle Scholar
  23. Gautvik KM, Talle K, Hager B, Jorgensen OG, Aas M (1989) Early liver metastases in patients with medullary carcinoma of the thyroid gland. Cancer 63: 175–180PubMedCrossRefGoogle Scholar
  24. Geelhoed GW, Bass BL, Mertz SL, Becker KL (1986) Somatostatin analog: effect on hypergastrinemia and hypercalcitoninemia. Surgery 100: 962–970PubMedGoogle Scholar
  25. Gordin A, Lamberg BA, Pelkonen R, Almquists (1987) Somatostatin inhibits the pentagastrin induced release of serum calcitonin in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 8: 289–293Google Scholar
  26. Gordon PR, Huvos AG, Strong EW (1973) Medullary carcinoma of the thyroid gland, a clinicopathologic study of 40 cases. Cancer 31: 915–924PubMedCrossRefGoogle Scholar
  27. Gorman B, Charbonean JW, James EM (1987) Medullary thyroid carcinoma: Role of high-resolution ultrasound. Radiology 162: 147–150Google Scholar
  28. Gottlieb JA, Hill CS (1974) Chemotherapy of thyroid cancer with adriamycin: experience with 30 patients. N Engl J Med 290: 193–197PubMedCrossRefGoogle Scholar
  29. Grauer A, Raue F, Gagel RF (1990) Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma. Endocrinol Metab Clin North Am 19: 613–635PubMedGoogle Scholar
  30. Guliana JM, Guillausseau PJ, Caron J, Siame-Mourot, Calmettes C, Modigliani E (1989) Effects of short-term subcutaneous administration of SMS 201–995 on calcitonin plasma levels in patients suffering from medullary thyroid carcinoma. Horm Metab Res 21: 584–586PubMedCrossRefGoogle Scholar
  31. Hales M, Rosenau W, Okerlund MD, Galante M (1982) Carcinoma of the thyroid with a mixed medullary and follicular pattern. Morphologic, immunhistochemical, and clinical laboratory studies. Cancer 50: 1352–1359Google Scholar
  32. Halnan KE (1975) The nonsurgical treatment of thyroid cancer. Surgery 62: 769–771Google Scholar
  33. Hazard JB, Hawk WA, Crile G (1959) Medullary (solid) carcinoma of the thyroid-a clinicopathologic entity. J Clin Endocrinol Metab 19: 152–161PubMedCrossRefGoogle Scholar
  34. Hellmann DE, Kartchner M, van Antwerp JD, Salmon SE, Patton D, O’Mara R (1979) Radioiodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 48: 4–11CrossRefGoogle Scholar
  35. Hoskin PJ, Harmer C (1987) Chemotherapy for thyroid cancer. Radiother Oncol 10: 187–194PubMedCrossRefGoogle Scholar
  36. Kakuda K, Carney A, Sizemore GW (1985) Medullary thyroid carcinoma of the thyroid, biological behavior of the sporadic and familial neoplasm. Cancer 55: 2818–2821CrossRefGoogle Scholar
  37. Keeling CA, Basso LV (1988) Iodine-131 MIBG uptake in metastatic medullary carcinoma of the thyroid. A patient treated with somatostatin. Clin Nucl Med 13: 260–263Google Scholar
  38. Kohlwagen R, Raue F, Winter J (1991) Register of medullary thyroid carcinoma in Germany. Acta Endocrinol (Copenh) 124, Suppl 1:Abstr 7Google Scholar
  39. Kraenzlin ME, Ch’ng JLC, Wood SM, Carr DH, Bloom SRC (1985) Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 88: 185–187PubMedGoogle Scholar
  40. Kvols LK (1988) The carcinoid syndrome: a treatable malignant disease. Oncology 2: 22–41Google Scholar
  41. Lamberts SWJ, Hofland LJ, van Koetsveld PM, Reubi JC, Bruining HA, Bakker WH, Krenning EP (1990) Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors, consequences with regard to diagnosis, localisation and therapy. J Clin Endocrinol Metab 71: 566–574PubMedCrossRefGoogle Scholar
  42. Lamberts SWJ, Krenning EP, Klijn JGM, Reubi JC (1990) Clinical applications of somatostatin analogs. Trends Endocrinol Metab 1: 139–145PubMedCrossRefGoogle Scholar
  43. Laurberg P (1984) Somatostatin and calcitonin release from perfused dog thyroid lobes; studies with calcium and pentagastrin. Endocrinology 114: 2234–2241PubMedCrossRefGoogle Scholar
  44. Libroia A, Verga U, di Sacco G, Piolini M, Muratori F (1989) Use of somatostatin analog SMS 201–995 in medullary thyroid carcinoma. Henry Ford Hosp Med J 37: 151–153PubMedGoogle Scholar
  45. Lippman SM, Mendelsohn G, Trump DL, Wells SA, Baylin SB (1982) The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase and histaminase. J Clin Endocrinol Metab 54: 233–240Google Scholar
  46. Ljungberg O (1966) Medullary carcinoma of the human thyroid gland: autoradiographic localization of radioiodine. Acta Pathol Microbiol Scand 68: 476–484PubMedGoogle Scholar
  47. Mahler C, Verhelst J, de Longueville M, Harris A (1990) Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf) 33: 261–269Google Scholar
  48. Modigliani E, Chayvialle JA, Cohen R, Perret G, Guliana JM, Vassy R, Roger P, Siame-Mourot C, Bennet M, Bentata-Pessayre M, Baulieu JL, Charpentier G, Rusniewsky P, Deidier A, Calmettes C (1988) Effect of a somatostatin analog (SMS 210–995) in perfusion on basal and pentagastrin-stimulated calcitonin levels in medullary thyroid carcinoma. Horm Metab Res 20: 773–775PubMedCrossRefGoogle Scholar
  49. Modigliani E, Alamowith C, Cohen R, Calmettes C, Guliana JM, Franc B, Bernard C, Chayvialle JA (1990) The intratumoral immunoassayable somatostatin concentration is frequently elevated in medullary thyroid carcinoma, results in 34 cases. Cancer 65: 224–228PubMedCrossRefGoogle Scholar
  50. Nieuwenhuijzen-Kruseman AC, Bussemarker JK, Frölich M (1984) Radioiodine in the treatment of hereditary medullary carcinoma of the thyroid. J Clin Endocrinol Metab 59: 491–494PubMedCrossRefGoogle Scholar
  51. Normann T, Gautvik KM, Johannessen JV, Brennhood IO (1976) Medullary carcinoma of the thyroid in Norway. Acta Endocrinol (Copenh) 83: 71–85Google Scholar
  52. Norton JA, Doppmann JL, Brennan MF (1980) Localization and resection of clinical inapparent medullary carcinoma of the thyroid. Surgery 87: 616–622PubMedGoogle Scholar
  53. Nusynowitz ML, Pollard E, Benedetto AR, Lecklitner ML, Ware RW (1982) Treatment of medullary carcinoma of the thyroid with I-131. J Nucl Med 23: 142–146Google Scholar
  54. Ott RA, Hofmann C, Oslaps R, Naggar R, Palogan E (1987) Radioiodine sensitivity of parafollicular C-cells in aged long-evens rats. Surgery 102: 1043–1048PubMedGoogle Scholar
  55. Pacini F, Elisei R, Anelli S, Basolo F, Cola A, Pincera A (1989) Somatostatin in medullary thyroid cancer, in vitro and in vivo studies. Cancer 63: 1186–1195CrossRefGoogle Scholar
  56. Pacini F, Basolo F, Elisei R, Fugazzola L, Cola A, Pincera A (1991) Medullary thyroid cancer, an immunohistochemical and humoral study using sex separate antigens. Am J Clin Pathol 95: 300–308PubMedGoogle Scholar
  57. Petursson SR (1988) Metastatic medullary thyroid carcinoma, complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 62: 1899–1903PubMedCrossRefGoogle Scholar
  58. Poster DS, Bruno S, Penta J, Pina K, Catane R (1981) Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland. Cancer Clin Trial 4: 301–307Google Scholar
  59. Rasmusson B, Hansen HS (1979) Treatment of medullary carcinoma of the thyroid: Value of calcitonin as tumor marker. Acta Radiol [Oncol] 18: 521–534Google Scholar
  60. Raue F, Minne H, Bayer JM (1976) Studies in endogenous hypercalcitoninaemia in man. 5th International Congress on Endocrinology, Hamburg, Abstr 386Google Scholar
  61. Raue F, Minne H, Ziegler R (1985) Cisplatin, adriamycin und vindesin, eine Kombinationschemotherapie beim differenzierten Schilddrüsencarcinom. Tumor Diagn Ther 6: 134–138Google Scholar
  62. Reichlin S (1990) Clinical application of somatostatin receptor imaging (Editorial). J Clin Endocrinol Metab 71: 564–565PubMedCrossRefGoogle Scholar
  63. Rougier P, Parmentier C, Laplanche A, Lefevre M, Travagli JP, Caillou B, Schlumberger M, Lacour J, Tubiana M (1983) Medullary thyroid carcinoma: prognostic factors and treatment. Int J Radiat Oncol Biol Phys 9: 161–169PubMedGoogle Scholar
  64. Ruhlmann J, Vogel J, Bockisch A, Biersack HJ (1987) Metastasen eines medullären Schilddrüsencarcinoms (folliculäre Variante) Diagnostik und Therapie mit Radiojod. Dtsch Med Wochenschr 112: 1170–1172PubMedCrossRefGoogle Scholar
  65. Saad MF, Guido JJ, Samaan NA (1983) Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 57: 124–128PubMedCrossRefGoogle Scholar
  66. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS, Hickey RC, Samaan NA (1984) Medullary carcinoma of the thyroid, a study of the clinical feature and prognostic factors in 161 patients. Medicine (Baltimore) 63: 319–342Google Scholar
  67. Samaan NA, Schultz PN, Hickey R (1988) Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol 67: 801–805CrossRefGoogle Scholar
  68. Samonigg H, Hossfeld DK, Spehn J, Fill H, Leb G (1988) Aclarubicin in advanced thyroid cancer: a phase II study. Eur J Cancer Clin Oncol 24: 1271–1275PubMedCrossRefGoogle Scholar
  69. Sarrazin D, Fontaine F, Rougier P, Gardet P, Schlumberger M, Travagli JP, Bounik H, Parmentier C, Tubiana M (1984) The role of external radiotherapy in the treatment of medullary thyroid carcinoma. Bull Cancer 71: 200–208PubMedGoogle Scholar
  70. Scherübl H, Raue F, Ziegler R (1990) Combination chemotherapy of advanced medullary and differentiated thyroid cancer, phase II study. J Cancer Res Clin Oncol 116: 21–23PubMedCrossRefGoogle Scholar
  71. Scherübl H, Raue F, Ziegler R (1990) Kombinationstherapie von Adriamycin, Cisplatin und Vindesin beim C-Zell-Karzinom der Schilddrüse. Onkologie 13: 198–202Google Scholar
  72. Schrezemeir J, Plewe G, Sturmer W, Kahaly G, Opperman D, Krause U, del Pozo E, Kaspar H, Beyer J (1986) Treatment of APUDomas with the longacting somatostatin analogue SMS 201–995. Scand J Gastroenterol 21 Suppl 119: 223–227CrossRefGoogle Scholar
  73. Schröder S, Böcker W, Baisch H, Bürk CG, Arps H, Meiners I, Kustendieck H, Heitz PU, Klöppel G (1988) Prognostic factors in medullary thyroid carcinomas, survival in relation to age, sex, stage, history, immunocytochemistry, and DNA content. Cancer 61: 806–816PubMedCrossRefGoogle Scholar
  74. Schwerk WB, Grün R, Wahl R (1985) Ultrasound diagnosis of C-cell carcinoma of the thyroid. Cancer 55: 624–630PubMedCrossRefGoogle Scholar
  75. Shah KH, Oslapas R, Calandra DB, Prinz RA, Ernst K, Hofmann C, Smith M, Chejfec, Lawrence AM, Polagan E (1983) Effects of radiation on parafollicular C-cells of the thyroid gland. Surgery 94: 989–994PubMedGoogle Scholar
  76. Shimoaka K (1980) Adjunctive management of thyroid cancer: chemotherapy. J Surg Oncol 15: 283–286CrossRefGoogle Scholar
  77. Shimoaka K, Schoenfeld DA, de Wys WD, Creech RH, de Conti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56: 2155–2160Google Scholar
  78. Simpson WJK (1975) Radiotherapy in thyroid cancer. Can Med Assoc J 113: 115–118PubMedGoogle Scholar
  79. Steinfeld AD (1977) The role of radiation therapy in medullary thyroid carcinoma of the thyroid. Radiology 123: 745–746PubMedGoogle Scholar
  80. Thurston V, Williams ED (1982) The effect of radiation on thyroid C-cells. Acta Endocrinol (Copenh) 92: 72–78Google Scholar
  81. Tisell L, Hansson G, Jansson S, Salander H (1986) Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99: 60–66PubMedGoogle Scholar
  82. Van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM (1990) Long-term course of patients with persistant hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212: 395–401PubMedCrossRefGoogle Scholar
  83. Wells SA, Baylin SB, Johnsrude JS, Harrington DP, Mendelsohn G, Ontjes DJ, Cooper CW (1982) Thyroid venous catheterization in the early diagnosis of familial medullary thyroid carcinoma. Ann Surg 196: 505–511PubMedCrossRefGoogle Scholar
  84. Wells SA, Baylin SB, Leight GS, Dale JK, Dilley WG, Farndon JR (1982) The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma. Ann Surg 195: 595–602PubMedCrossRefGoogle Scholar
  85. Williams SD, Birch R, Einhorn LH (1986) Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a southeastern cancer study group trial. Cancer Treat Rep 70: 405–407PubMedGoogle Scholar
  86. Woolner LB, Beahrs OH, Blach BM, McConahey WM, Keating FR (1961) Classification and prognosis of thyroid carcinoma, a study of 885 cases observed in a thirty year period. Am J Surg 102: 354–387PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1992

Authors and Affiliations

  • F. Raue
    • 1
  1. 1.Abteilung für Innere Medizin I - Endokrinologie und StoffwechselUniversität HeidelbergHeidelberg 1Germany

Personalised recommendations